HOME >> BIOLOGY >> NEWS
FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia

Berlex Laboratories to market a new option for patients with refractory, or hard-to-treat, B-CLL

MONTVILLE, N.J., May 8, 2001 The U.S. Food and Drug Administration (FDA) late yesterday cleared Campath (alemtuzumab) humanized monoclonal antibody for marketing as a treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) who have been treated with alkylating agents and have failed fludarabine therapy. With this decision, Berlex Laboratories, Inc., the U.S. affiliate of Schering AG, Germany (NYSE: SHR), will provide patients with refractory B-CLL a new treatment option. Campath therapy for B-CLL was developed by M&I Partners, a 50-50 joint venture of Millennium Pharmaceuticals, Inc., (NASDAQ: MLNM) and ILEX Oncology, Inc., (NASDAQ: ILXO). Campath will be marketed and distributed in the United States by Berlex Laboratories, Inc., of Montville, N.J.

This approval is good news for patients with refractory B-CLL. Campath provides a new option for refractory patients who have no other approved therapeutic options available, said Kanti Rai, M.D., chief of the division of hematology and oncology, Long Island Jewish Medical Center and a principal investigator in the Campath clinical trials.

Chronic lymphocytic leukemia is the most prevalent form of adult leukemia, affecting approximately 120,000 patients in the U.S. and Europe. B-CLL is characterized by an accumulation of leukemic (malignant) lymphocytes that often bear the CD52+ antigen, in the bone marrow, blood, and other tissues. As a result of the accumulation of malignant lymphocytes, bone marrow dysfunction and enlargement of the lymph nodes, liver, and spleen may occur. Patients with B-CLL may suffer from disease-related symptoms such as fatigue, bone pain, night sweats, and decreased appetite and weight loss.

Campath appears to work by targeting the CD52+ antigen on the malignant lymphocytes. Campath binds to CD52+, an antigen
'"/>

Contact: Richard Salem
973-487-2371
Porter Novelli
7-May-2001


Page: 1 2 3 4

Related biology news :

1. FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition
2. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
3. FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis
4. FDA approves Abbotts Biaxin XL (clarithromycin extended-release tablet)for community-acquired pneumonia
5. DFG approves 14 new research training units
6. National Science Board approves five new NSF Science and Technology Centers
7. MCG pursues markers to improve ovarian cancer treatment, diagnosis
8. Chronic pain: treatment, rehabilitation, and quality of life
9. Lens replacement material may improve cataract treatment, eliminate bifocals
10. Researchers discover possible diagnosis, treatment, vaccine for mad cow, prion diseases
11. Many pregnant women may have depression, but few getting treatment, study finds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/29/2019)... ... October 29, 2019 , ... ... for biopharmaceutical R&D, today announced that Octapharma, one of the world’s largest ... support the development and manufacturing of therapeutic proteins addressing severe diseases in ...
(Date:10/26/2019)... ... October 23, 2019 , ... Medrio is pleased to announce ... leadership team. , As a market leader in solutions for EDC, Direct Data ... to reduce timelines and improve quality with real-time data capture. In her ...
(Date:10/26/2019)... N.J. (PRWEB) , ... October ... ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... two presentations during the “Manufacturing and Bioprocessing Track” at the forthcoming American ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... ... October 30, 2019 , ... ... showcase the many roles innovation and technology play in educating the next generation ... featured hands-on learning opportunities and presentations by WesternU administrators and representatives of companies ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... skin*. Using Silios CMS-C multispectral imagers , researchers identified people by the ... identification based on retinal imaging, face recognition, fingerprints and vasculature. , The ...
(Date:10/22/2019)... SOMERSET, N.J. (PRWEB) , ... October 22, 2019 , ... ... Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel ... Logistics Conference (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, ...
(Date:10/17/2019)... PARK, Kan. (PRWEB) , ... October 15, 2019 ... ... to 23andMe, a leader among services that offer DNA Testing for health and/or ... so popular. Everywhere you look, it seems that people want to know more ...
Breaking Biology Technology:
Cached News: